Are the Current Recommendations for Chloroquine and Hydroxychloroquine Screening Appropriate?

Authors :: Schwartzman S
Samson CM
Source :: Rheumatic diseases clinics of North America [Rheum Dis Clin North Am] 2019 Aug; Vol. 45 (3), pp. 359-367. Date of Electronic Publication: 2019 May 30.
Publication Year :: 2019
Abstract: Hydroxychloroquine and quinacrine are frequently used to treat rheumatic diseases. Ocular toxicity, although infrequent, is one of the potential side effects of antimalarial therapies. Current recommendations are unifocal in being developed by only ophthalmologists who do not treat patients for their rheumatic diseases. The data used to create the recommendations are meager and retrospective. Comanagement of patients with rheumatic disease who are exposed to antimalarial therapies requires a greater interaction between ophthalmologists and rheumatologists.<br /> (Copyright © 2019 Elsevier Inc. All rights reserved.)

Subjects :: Antimalarials adverse effects
Antimalarials therapeutic use
Humans
Patient Care Management methods
Patient Care Management standards
Risk Adjustment
Chloroquine adverse effects
Chloroquine therapeutic use
Eye Diseases chemically induced
Eye Diseases prevention & control
Hydroxychloroquine adverse effects
Hydroxychloroquine therapeutic use
Rheumatic Diseases drug therapy

Full Text Access

Tools